1. Home
  2. MFM vs CCCC Comparison

MFM vs CCCC Comparison

Compare MFM & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFS Municipal Income Trust

MFM

MFS Municipal Income Trust

HOLD

Current Price

$5.36

Market Cap

222.4M

Sector

Finance

ML Signal

HOLD

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$2.08

Market Cap

240.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MFM
CCCC
Founded
1986
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
222.4M
240.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
MFM
CCCC
Price
$5.36
$2.08
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$7.25
AVG Volume (30 Days)
108.1K
2.0M
Earning Date
01-01-0001
11-06-2025
Dividend Yield
4.08%
N/A
EPS Growth
N/A
N/A
EPS
0.03
N/A
Revenue
N/A
$30,108,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$176.67
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.37
$1.09
52 Week High
$5.48
$4.26

Technical Indicators

Market Signals
Indicator
MFM
CCCC
Relative Strength Index (RSI) 46.65 38.53
Support Level $5.40 $1.93
Resistance Level $5.45 $2.13
Average True Range (ATR) 0.06 0.15
MACD -0.01 -0.05
Stochastic Oscillator 26.67 18.07

Price Performance

Historical Comparison
MFM
CCCC

About MFM MFS Municipal Income Trust

MFS Municipal Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in municipal bonds.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Share on Social Networks: